Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22322037 | 0.87 | TUBB1 (0.62) | ALDH1A1MAOBCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL5654410 | 0.86 | ALDH1A1 (0.63) | ALDH1A1MAOBL3MBTL1CYP1A2CYP1A1 | |
| SCHEMBL22322045 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAOBL3MBTL1CYP1A2TUBB1 | |
| SCHEMBL702232 | 0.85 | ALDH1A1 (0.71) | ALDH1A1MAOBL3MBTL1CYP1A2CYP1A1 | |
| SCHEMBL14539352 | 0.83 | ALDH1A1 (0.69) | ALDH1A1MAOBL3MBTL1CYP1A2CYP1A1 | |
| SCHEMBL3905573 | 0.83 | ALDH1A1 (0.69) | ALDH1A1MAOBL3MBTL1CYP1A2CYP1A1 | |
| SCHEMBL5143349 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAOBL3MBTL1CYP1A2CYP1A1 | |
| Ethylene SCHEMBL4914414 | 0.82 | ALDH1A1 (0.92) | ALDH1A1L3MBTL1CYP1A2CYP1A1CYP1B1 | |
| Formaldehyde SCHEMBL28854145 | 0.82 | ALDH1A1 (0.92) | ALDH1A1L3MBTL1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL96291 | 0.82 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1CYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921320-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BeiGene, Ltd. (KY) | 2021-12-15 | — | — | EP | disclosed |
| CN-113454086-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020160711-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE, LTD. (KY) | 2020-08-13 | — | — | WO | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| US-7244743-B2 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | BRS3, NPR3, ADRB3 | ALDH1A1 3634/4885MAOB 2381/4885L3MBTL1 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.